A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F, Bedossa P, Sun X, Hoshida Y, Koduru SV, Contaifer D, Warncke UO, Wijesinghe DS, Sanyal AJ. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal Of Hepatology 2016, 65: 579-588. PMID: 27261415, PMCID: PMC5012902, DOI: 10.1016/j.jhep.2016.05.005.Peer-Reviewed Original ResearchConceptsNon-alcoholic steatohepatitisNon-alcoholic fatty liver diseaseDiet-induced animal modelsProgressive non-alcoholic steatohepatitisHuman non-alcoholic steatohepatitisFatty liver diseaseHepatocellular cancerLiver diseaseAnimal modelsDiet-induced mouse modelGene signatureHigh-fat dietSimilar histological phenotypesAd libitum consumptionProgressive fibrosisLDL cholesterolChow dietMice fedInsulin resistanceFat dietClinical endpointsHuman NAFLDObesogenic dietPreclinical modelsMouse modelMolecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016, 65: 1049-1061. PMID: 26997538, PMCID: PMC4931958, DOI: 10.1016/j.metabol.2016.02.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCCAAT/enhancer-binding homologous proteinNonalcoholic fatty liver diseasePKR-like ER kinaseFatty liver diseaseP53 upregulated modulatorEndoplasmic reticulum stressGlucose intoleranceHepatocellular injuryPharmacological therapyLiver diseaseMetabolic derangementsInsulin resistanceHepatocyte injuryLipotoxic stateC-Jun NH2-terminal kinase 1Exposure of hepatocytesHigh fructoseProtective roleEnergy homeostasisUpregulated modulatorGlucose dietLipotoxicityMitochondrial impairmentOxidative stressReticulum stressNonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options
Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clinical Medicine Insights Therapeutics 2016, 8: cmt.s18885. PMID: 28670148, PMCID: PMC5491796, DOI: 10.4137/cmt.s18885.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNonalcoholic fatty liver diseaseLiver diseaseManagement of NAFLDPathogenesis of NAFLDAdvanced phase clinical trialsLiver-related outcomesCornerstone of treatmentFirst-line therapyHigh-risk patientsChronic liver diseaseFatty liver diseaseCurrent treatment optionsHepatic manifestationNAFLD patientsMetabolic syndromeMajor etiologyInsulin resistancePharmacologic interventionsTreatment optionsClinical evaluationClinical trialsHigh riskVitamin ENatural historyPatients